<

UCB (EBR:UCB) UCB Media Room: First Three Months Interim Report 2018

Transparency directive : regulatory news

25/04/2018 18:00

UCB First Three Months Interim Report 2018: UCB tracking well towards full year financial outlook

Brussels (Belgium), 25 April 2018 – 18:00 (CEST) – regulated information – 

  •  Revenue reached € 1.07 billion: -5%, -1% CER; adjusted for allergy drug divestiture in 2017: +0%; +4% CER
  • UCB’s main five products reached € 839 million (-2%, +8% CER)
  • R&D update: Cimzia® available for women with chronic inflammatory disease throughout the pregnancy journey; UCB0107 enters clinical phase 1; Element Genomics strengthens research platform; agreement to acquire midazolam nasal spray in epilepsy 
  • Financial outlook 2018 confirmed: Revenue expected to reach € 4.5 - 4.6 billion, recurring EBITDA2 should reach € 1.3 - 1.4 billion, Core EPS of € 4.30 - 4.70

Open PDF of "UCB First Three Month Interim Report 2018 ENG"

Open PDF of "UCB First Three Month Interim Report 2018 FR"

Open PDF of "UCB First Three Month Interim Report 2018 NL"

 



If you would rather not receive future communications from UCB SA, let us know by clicking here.
UCB SA, Allée de la Recherche, 60 ., Brussels, . B - 1070 Belgium


Other stories

24/04/2024 20:08
24/04/2024 19:13
24/04/2024 18:30
24/04/2024 18:30
24/04/2024 17:10
24/04/2024 19:10
24/04/2024 15:14
24/04/2024 11:46
24/04/2024 16:55
24/04/2024 09:13
24/04/2024 13:44
24/04/2024 17:27
24/04/2024 17:31
24/04/2024 11:51
24/04/2024 12:19
24/04/2024 18:04
24/04/2024 16:07
24/04/2024 08:47
24/04/2024 12:00
24/04/2024 16:00
24/04/2024 13:46
24/04/2024 09:45
24/04/2024 20:15
24/04/2024 14:05
24/04/2024 12:18
24/04/2024 19:30
24/04/2024 20:13
24/04/2024 20:13
24/04/2024 21:07
24/04/2024 20:07
24/04/2024 07:30
24/04/2024 08:05
24/04/2024 01:01
23/04/2024 12:10
24/04/2024 14:25
24/04/2024 18:32
24/04/2024 09:15
24/04/2024 13:26